Headlight’s Post

Very interesting ! 😄 Targeting the frontaltemporal area seems promising as these areas, especially the frontal lobe, are the sites of executive functionning which play a huge role in overal self regulation and a lesion or malfunction of these areas may make people mote lilely to make irrrelevant choices / addictive behaviors. In fact, frontaltemporal dementia actually clinivally enlights behavioral issues. Now my question is ; how exactly does neuromodulation work? Looking forward to seeing the evolution!

Congratulations to Paul VanVeldhuisen on co-authoring the research paper, “Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment,” published in JAMA Psychiatry. This recently developed prediction model, which was developed by harmonizing clinical trial data from 3 completed studies conducted in the National Institute on Drug Abuse Clinical Trials Network, can be used as a risk measure to help predict those who may return to opioid use after starting treatment. Read about the research effort at https://hubs.la/Q025vlmY0

Exciting News! Unveiling the Latest Research on Ketogenic Metabolic Therapy for Depression. This Therapy Holds the Potential to Be a First-Line Treatment for Brain Energy Disorders. It's Vital for Everyone to Know About This Promising Option in Metabolic Psychiatry! https://lnkd.in/eRaVx7uQ

Congratulations to @Paul Van Veldhuisen on co-authoring the research paper, “Individual-Level Risk Prediction of Return to Use During Opioid Use Disorder Treatment,” published in JAMA Psychiatry. This recently developed prediction model, which was developed by harmonizing clinical trial data from 3 completed studies conducted in the National Institute on Drug Abuse Clinical Trials Network, can be used as a risk measure to help predict those who may return to opioid use after starting treatment. Read about the research effort at https://hubs.la/Q025vKxv0

Amazing work done in the pursuant towards #precisionmedicine and treatment of psychiatric conditions along with #AI If you are interested check out the link below in the post for the full PDF on the clinical trial design and data. Great stuff!

Many people diagnosed with depression also have brain inflammation (1). Could this explain why roughly 1/3 of patients do not respond to traditional psychiatric medications? We at the Brain Inflammation Collaborative envision a world where the causes of treatment-resistant depression are widely understood, promptly diagnosed, and treated. Join our mission by sharing this with your family, friends, and colleagues. Literature Cited: Role of Translocator Protein Density, a Marker of Neuroinflammation, in the Brain During Major Depressive Episodes | Radiology | JAMA Psychiatry | JAMA Network Quote Source: https://lnkd.in/dfkGzzcv #depression #treatmentresistantdepression #SSRI

Next lecture on Philosophy & Psychiatry Seminar (Institut društvenih nauka - Institute of Social Sciences): “The Drug Worked for Me” … But Did It? Jacob Stegenga (with Hamed Tabatabaei Ghomi) In his presentation, Dr Jacob Stegenga will question whether inferences from patients' first-person experiences about the effectiveness of their prescribed psychiatric drugs are reliable. Join us on April 18, 11.00 CET! 🙂 https://lnkd.in/dXymfvE5

The process of onboarding psychiatric medications takes three weeks for the drug to penetrate the blood-brain barrier and determine its suitability for the patient. However, the prescribing of these medications is complicated by sub-optimal efficacy and high rates of adverse drug reactions, which is a concern in psychiatry. Currently, the selection of antipsychotics and antidepressants is often based on a trial-and-error approach, which is far from ideal. To address this issue, the field of pharmacogenetics (PGx) comes into play, considering how genetic variations can impact an individual's response to a drug. By incorporating PGx testing, clinicians can make more informed decisions when choosing psychotropic medications, leading to a more personalized and effective approach to prescribing. Ultimately, this could enhance the utilization and adherence to these medications, leading to better outcomes for patients.

One of the Top GEN Articles of 2023: Alto Neuroscience Announces Positive Phase II Results Supporting Precision Psychiatry Platform On Day 2 of the annual J.P. Morgan Healthcare Conference, Alto’s founder and CEO Amit Etkin, MD, PhD, details the company’s Precision Psychiatry Platform and the safety and efficacy of ALTO-100 in patients with major depressive disorder (MDD). https://ow.ly/c8YR50QlWby

[For Academy Students: RSVP for a Live Session tomorrow] Comparing Antipsychotics: with Pneumonia Risk [Understanding the Anticholinergic Burden] On June 26, 2024: JAMA Psychiatry published this cohort study of people with schizophrenia to assess the association of antipsychotics with pneumonia. In this upcoming Live video, Dr. Harvinder Singh will summarize this findings to answer the following questions: (1) Mechanism: What is the likely mechanism(s) behind antipsychotics induced pneumonia risk? (2) Risk Factors: Which patients with schizophrenia are more at risk? (3) Antipsychotics Dose: Can dose of antipsychotics impact the pneumonia risk? (4) Risk for Antipsychotics Monotherapy vs Polytherapy. (5) Comparing Antipsychotics: Which antipsychotics have HIGHEST & LOWEST risk of Pneumonia? RSVP here: https://lnkd.in/gChBVMg6